Who is sponsoring NCT04898374?

NCT04898374 is sponsored by Kuwait Cancer Control Center.

What drugs are being tested in NCT04898374?

Interventions in NCT04898374: Gemcitabin/cisplatin.

What condition does NCT04898374 study?

NCT04898374 studies Nasopharyngeal Carcinoma.

Is NCT04898374 still recruiting?

NCT04898374 is currently recruiting now. Last updated 17 August 2022.

Last reviewed 2022-08-17 · How we verify

NCT04898374

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

Recruiting now Phase 3 Last updated 17 August 2022

What this trial tests

Phase 3 trial testing Gemcitabin/cisplatin in Nasopharyngeal Carcinoma in 120 participants. Currently enrolling.

Timeline

1 May 2021

Primary endpoint
30 April 2025

30 April 2026

Quick facts

Lead sponsor	Kuwait Cancer Control Center
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 May 2021
Primary completion	30 April 2025
Estimated completion	30 April 2026
Sites	1 location across Kuwait

Drugs / interventions tested

Gemcitabin/cisplatin — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Kuwait Cancer Control Center — full company profile →

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of life.However distant failure is still the main challenging reason of poor survival Addition of systemic therapy to concurrent CRT is widely used and accepted as an option to reduce these failures ,however selection of chemotherapy regimen and timing in relation to CRT is controversial. Doublet and triplet chemotherapy regimens using cisplatin and 5FU are throughly investigated in this setting.Inspite of significant improvement in disease free survival and overall survival they were poorly tolerated.Hence,minority of patients in the daily practice could tolerate those studied regimens as propsed. Recently, in multicenter randomized trial, Zhang and his group investigated gemcitabine and cisplatin as induction chemotherapy (ICT) added to CRT.It showed improvement in recurrence free survival and overall survival.More importantly 96.7% of the experimental arm completed the treatment protocol. This was further confirmed by an updated network of meta analysis by Bongiovanni et al.Again the question of "when" is still valid.Our proposal is to compare tolerable regimen in induction versus adjuvant settings.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Metabolic Vulnerabilities in Epstein-Barr Virus-Driven Proliferative Diseases.
Leung NYT, Wang LW. · · 2023 · cited 4× · PMID 37444521 · DOI 10.3390/cancers15133412
Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II-IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis.
Yang J, Liang ZG, Jiang YT, Chen KH, et al · · 2021 · cited 3× · PMID 34926289 · DOI 10.3389/fonc.2021.778836

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Kuwait Cancer Control Center trials

Trials by the same sponsor.

NCT03532737 — Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04898374 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kuwait Cancer Control Center
Last refreshed: 17 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04898374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing